New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated two add two new products, including BioMarin’s Voxzogo (vosoritide) for treating achondroplasia in children.
You may also be interested in...
Ryzneuta, Evive Biotech’s treatment for chemotherapy-induced neutropenia in cancer patients, is among the latest new medicines that have been submitted for review for potential pan-EU approval.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.